Please note that the NHR is unable to analyse the data concerning the set-up of several studies due to the changeover to HRA Approval. There are therefore 9 studies that cannot be included in this report. 3 of these studies achieved the 70-day benchmark, and BSUH was only implicated in the reasons for the delay of 1 of the 6 studies that did not meet the benchmark.

| | | | | | | | | | | | | Reasons for not achieving the 70 day target from receipt of valid research application to 1st patient recruited | | | | | | | | | |
|--|---------|--|----------------------|------------------------|----------------------|-----------------------------------|---------------------|---|----------------------------------|------------------------------------|--|---|--------------------------|-----------------------|-------------------------------------|-------------------------|------------------------------|------------------------------|--------------------|-----------|--|
| Research Ethics Committee Reference Number | IRAS no | Full Name of Trial | Site invitation date | Site selection date | HRA Approval date | Date site confirmed by Sponsor | Date site confirmed | Non-confirmation status (if applicable) | Date when site ready to start | Date of First Patient Recruited | A - Permissions delayed/denie d | B - Suspended by sponsor | C - Closed by sponsor | D - Sponsor Delays | E - Staff availability issues | F - No patients seen | G - No patients consented | H - Contracting delays | I-Rare diseases | J - Other | Study team comments Reasons for delay correspond to: |
| 16/YH/0157 | 204585 | PLATO - Personal Lising Anal cancer radio Therapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5 | 21/07/2016 | 21/07/2016 | 20/07/2016 | | | | | | Υ | | | | | | | | | | Capacity and capability not completed within target timeframe. Decision is yet to made about whether this study will enter set-up, so HRA pack was Both received prematurely. |
| 16/SC/0147 | 183044 | TRIMASTER V1: Randomised Double-Blind Crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiszolidinedone as third line therapy in patients with type 2 diabetes who have suboptimal glycenemic control on dual therapy with metformin and a sulphonyturea. | 20/05/2016 | 01/08/2016 | 07/07/2016 | | | | | | | | | Y | | | | | | | Sponsor has delayed start date until early 2017 as they are unable to get the pharmacy supplies until the end of November 2016 at the earliest. |
| 16/LLO/1113 | 209455 | GEMINI 2 (205543) A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of doublegravir pix instruden compared to doublegravir pix stendoutrientricitabine in HIV-1-infected treatment-naïve adults | 03/05/2016 | 13/09/2016 | 05/09/2016 | 13/07/2016 | 14/07/2016 | | 21/09/2016 | 08/11/2016 | | | | | | | | | | | 70 day target met Neither |
| 15/LO/1904 | 173980 | The Impact of Multiparametric MRI on the Staging and Management of Patients with suspected or confirmed Ovasian Cancer | 11/10/2016 | 11/10/2016 | 09/08/2016 | 16/11/2016 | 29/11/2016 | | 09/12/2016 | | | | | | Υ | | | | | | As at 31.12.16, radiographers and radiologists hadn't completed the training required. One on on long term sickness, one on maternity leave. |
| 16/LO/1811 | 214264 | A Phase II, Randomized, Double-Blind, Placebo Controlled Saxly of the Safety and Efficacy of GDC-0853 in Patients with Moderate to Severe Active Systemic Lupus Erythematosus | 31/08/2016 | 11/10/2016 | 05/12/2016 | 07/12/2016 | 13/12/2016 | | | | | | | | Υ | | | | | | There was a delay in opening the study due to difficulty finding a mutually convenient date for the StV. |
| 15/WM/0276 | 207822 | SNIFFLE: Safety of Nasal Influenza Immunisation in Children with Asthma | 14/07/2016 | 13/10/2016 | 22/08/2016 | 20/09/2016 | 04/10/2016 | | 13/10/2016 | 27/10/2016 | | | | | | | | | | | 70 day target met Neither |
| 16/LO/1940 | 213099 | An open label, single arm, multicenter, safety study of alezolizumab in locally advanced or metastatic urofhelial or non-urofhelial cardinoma of the urinary tract. | 14/10/2016 | 19/10/2016 | | | | | | | Y | | | | | | | | | | HRA pack received quickly from Sporsor, but local capacity & capabity not yet confirmed. Still Neither awaiting HRA Approval. |
| 16/LO/1891 | 213918 | A Phase 2, Double-Bind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Predriscione versus Predrisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH) | 19/08/2016 | 09/11/2016 | | 19/12/2016 | 21/12/2016 | | | | | | | | | | | | | | Still within target timeframe, but likely to breach target as the approval of an amendment to include transjugular biopsies is required before the SIV can be held. |
| 13/LO/1691 | 135504 | An open-label phase (/randomised, double blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 In combination with Docetaxel and prednisolone chemotherapy | 16/05/2016 | 10/11/2016 | 23/06/2016 | 10/11/2016 | 14/11/2016 | | | | | | | | | | | | | | Still within target timeframe Neither |
| 16/LO/0831 | 196728 | CAP IT: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoudoillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial | 14/07/2016 | 18/11/2016 | 11/11/2016 | | | | | | | | | | | | | | | | Still within target timeframe Neither |
| 16/EE/0463 | 214371 | An open-label, millioenter, Phase IIII study to assess the safety and efficacy of inhocials (LEEO11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HER2) advanced breast cancer (ABC) with no prior hormonal therapy for advanced breast cancer (ABC) with no prior hormonal therapy for advanced desease. CANS 31440. | 31/10/2016 | 18/11/2016 | | 24/11/2016 | 28/11/2016 | | | | | | | | | | | | | | Still within target timeframe. HRA pack received 18.11.16 but no manuals included - sponsor states they will not be providing these even though our site requires them. SIV scheduled 12.17 |
| 16/EM/0386 | 211113 | CAMG334A2301: A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous AMG 334 (x mg) against placebo in adult patients with episcoic migraine who have failed 2- 4 prophylactic migraine treatments. | 23/09/2016 | 08/12/2016 | | | | | | | | | | | | | | | | | Still within target timeframe. Lab manual received 8.12.16 - this completes minimum doc set. Amendment in progress, sponsor requested that SIV be delayed. Neither |
| 16/LO/1854 | 184654 | A Phase 3. Randomized, Double-blind Study to Evolutate the Safety and Efficacy of Erricitation and Tenorivi Alahamanike (FTAF) Fisch-Dose Continuation Once Daily for Pre-Exposure Prophylasis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection | 10/10/2016 | 14/12/2016 | 14/12/2016 | 01/11/2016 | 02/11/2016 | | 21/12/2016 | | | | | | | | | | | | Still within target timeframe Neither |